Beam Therapeutics Inc. (NASDAQ:BEAM) has seen 0.82 million shares traded in the recent trading session. The company, currently valued at $4.83B, closed the recent trade at $67.39 per share which meant it lost -$2.97 on the day or -4.22% during that session. The BEAM stock price is -105.55% off its 52-week high price of $138.52 and 16.4% above the 52-week low of $56.34. If we look at the company’s 10-day average daily trading volume, we find that it stood at 0.53 million shares traded. The 3-month trading volume is 562.45K shares.
The consensus among analysts is that Beam Therapeutics Inc. (BEAM) is an Overweight stock at the moment, with a recommendation rating of 1.70. 0 analysts rate the stock as a Sell, while 0 rate it as Overweight. 3 out of 11 have rated it as a Hold, with 8 advising it as a Buy. 0 have rated the stock as Underweight. The expected earnings per share for the stock is -$1.04.
3 Tiny Stocks Primed to Explode The world’s greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We’ve set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Sporting -4.22% in the red today, the stock has traded in the red over the last five days, with the highest price hit on Friday, 01/07/22 when the BEAM stock price touched $67.39 or saw a rise of 18.43%. Year-to-date, Beam Therapeutics Inc. shares have moved -11.71%, while the 5-day performance has seen it change -11.71%. Over the past 30 days, the shares of Beam Therapeutics Inc. (NASDAQ:BEAM) have changed -11.31%. Short interest in the company has seen 5.51 million shares shorted with days to cover at 8.26.
Wall Street analysts have a consensus price target for the stock at $121.89, which means that the shares’ value could jump 44.71% from the levels at last check today. The projected low price target is $85.00 while the price target rests at a high of $159.00. In that case, then, we find that the latest price level in today’s session is -135.94% off the targeted high while a plunge would see the stock gain -26.13% from the levels at last check today.
Beam Therapeutics Inc. (BEAM) estimates and forecasts
Figures show that Beam Therapeutics Inc. shares have underperformed across the wider relevant industry. The company’s shares have lost -28.49% over the past 6 months, with this year growth rate of -112.72%, compared to 7.80% for the industry. Other than that, the company has, however, lowered its growth outlook for the 2022 fiscal year revenue. Growth estimates for the current quarter are 38.50% and 69.00% for the next quarter. Revenue growth from the last financial year stood is estimated to be 7,441.70%.
8 analysts offering their estimates for the company have set an average revenue estimate of $1.13 million for the current quarter. 5 have an estimated revenue figure of $1.7 million for the next quarter concluding in Mar 2022.
Earnings growth for 2022 is a modest -108.70% while over the next 5 years, the company’s earnings are expected to increase by 2.70%.
Beam Therapeutics Inc. is expected to release its next earnings report between March 14 and March 18 this year, and investors are excited at the prospect of better dividends despite the company’s debt issue.
Beam Therapeutics Inc. (NASDAQ:BEAM)’s Major holders
Insiders own 2.05% of the company shares, while shares held by institutions stand at 78.20% with a share float percentage of 79.83%. Investors are also buoyed by the number of investors in a company, with Beam Therapeutics Inc. having a total of 309 institutions that hold shares in the company. The top two institutional holders are ARK Investment Management, LLC with over 6.84 million shares worth more than $595.3 million. As of Sep 29, 2021, ARK Investment Management, LLC held 10.04% of shares outstanding.
The other major institutional holder is Vanguard Group, Inc. (The), with the holding of over 4.52 million shares as of Sep 29, 2021. The firm’s total holdings are worth over $393.0 million and represent 6.63% of shares outstanding.
Also the top two Mutual Funds that are holding company’s shares are ARK ETF Tr-ARK Innovation ETF and ARK ETF Tr-ARK Genomic Revolution ETF. As of Oct 30, 2021, the former fund manager holds about 8.21% shares in the company for having 5.59 million shares of worth $496.4 million while later fund manager owns 2.28 million shares of worth $202.07 million as of Oct 30, 2021, which makes it owner of about 3.34% of company’s outstanding stock.